i3 Pharmaceuticals

About i3 Pharmaceuticals

i3 Pharmaceuticals, LLC is a privately owned pharmaceutical company established in September 2015, focusing on the research, development, and manufacture of high technological barrier, solid oral generic specialty pharmaceutical products. Located in a state-of-the-art 150,000 square foot facility in Warminster, PA, the company has made substantial capital investments to ensure top-notch production capabilities. The company serves clients in the pharmaceutical industry who require complex formulations, including sustained release, extended release, and delayed release formulations, as well as solutions for poorly soluble drugs, unstable molecules, and potent compounds. i3 Pharmaceuticals operates in the highly competitive generic pharmaceutical market, where it differentiates itself through its expertise in creating technically challenging products. The business model revolves around developing and manufacturing these specialized pharmaceuticals and bringing them to market, generating revenue through the sale of these high-quality, difficult-to-formulate products. The company passed its first Prior Approval and GMP inspection following its first ANDA filing in 2018, underscoring its commitment to quality and regulatory compliance.